Right sided heart failure and pulmonary hypertension: New insights into disease mechanisms and treatment modalities. (December 2016)

• Record Type: Journal Article
• Authors: Drogalis-Kim, Diana; Jefferies, John; Wilmot, Ivan; Alejos, Juan
• Is Part Of: Progress in pediatric cardiology. Volume 43(2016)
• Page Start: 71
• Page End: 80
• Publication Date: 2016-12
• Subjects: cGMP cyclic guanosine monophosphate -- PDE5-I Prosphodiesterase type 5 inhibitor -- PDE5 Prosphodiesterase type 5 -- 5′GMP 5′ Guanosine monophosphate -- cAMP cyclic adenosine monophosphate -- ETRA Endothelin receptor antagonist -- AC adenylate cyclase; Pediatric cardiology -- Periodicals; Cardiovascular Diseases -- Periodicals; Infant; Child; Cardiologie pédiatrique -- Périodiques; 618.9212005
• DOI: 10.1016/j.ppedcard.2016.05.002
• Languages: English
• ISSNs: 1058-9813

Abstract

Abstract: Pulmonary hypertension (PH), a rare chronic progressive disorder, is a well-established cause of right heart failure. Given that right heart function is the most important determinant of PH patient longevity Sandoval et al. (1994), D'Alonzo et al. (1991), Benza et al. (2010)[1–3], right heart pressure overload and failure secondary to PH is a critical aspect of the disease to review. In this article, we will highlight new research on the mechanisms of PH induced right heart failure, as well as review the latest PH treatments aimed at improving or sustaining right heart function.